In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Gain Therapeutics Inc (NASDAQ: GANX) closed the day trading at $1.09 up 1.87% from the previous closing price of $1.07. In other words, the price has increased by $1.87 from its previous closing price. On the day, 0.56 million shares were traded. GANX stock price reached its highest trading level at $1.27 during the session, while it also had its lowest trading level at $1.08.
Ratios:
For a better understanding of GANX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.84 and its Current Ratio is at 2.84. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.04.
On April 12, 2021, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $30.
On April 12, 2021, BTIG Research started tracking the stock assigning a Buy rating and target price of $30.BTIG Research initiated its Buy rating on April 12, 2021, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 09 ’24 when Mack Gene bought 14,400 shares for $1.01 per share. The transaction valued at 14,544 led to the insider holds 14,400 shares of the business.
Islam Khalid bought 50,000 shares of GANX for $49,940 on Aug 09 ’24. The Executive Chairman now owns 50,000 shares after completing the transaction at $1.00 per share. On Jul 01 ’24, another insider, RICHMAN ERIC I, who serves as the Director of the company, bought 17,000 shares for $1.22 each. As a result, the insider paid 20,670 and bolstered with 289,629 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GANX now has a Market Capitalization of 27833696 and an Enterprise Value of 11704906.
Stock Price History:
Over the past 52 weeks, GANX has reached a high of $5.33, while it has fallen to a 52-week low of $0.89. The 50-Day Moving Average of the stock is -8.08%, while the 200-Day Moving Average is calculated to be -60.38%.
Shares Statistics:
Over the past 3-months, GANX traded about 405.87K shares per day on average, while over the past 10 days, GANX traded about 694250 shares per day. A total of 25.54M shares are outstanding, with a floating share count of 23.70M. Insiders hold about 7.21% of the company’s shares, while institutions hold 11.89% stake in the company. Shares short for GANX as of 1723680000 were 188193 with a Short Ratio of 0.46, compared to 1721001600 on 83753. Therefore, it implies a Short% of Shares Outstanding of 188193 and a Short% of Float of 0.77.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 3.0 analysts currently analyzing and rating the stock of Gain Therapeutics Inc (GANX).The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.18 and low estimates of -$0.23.
Analysts are recommending an EPS of between -$1.01 and -$1.08 for the fiscal current year, implying an average EPS of -$1.05. EPS for the following year is -$0.98, with 2.0 analysts recommending between -$0.82 and -$1.15.
Revenue Estimates
2.0 analysts predict $nan in revenue for the current quarter. It ranges from a high estimate of $nan to a low estimate of $nan. As of the current estimate, Gain Therapeutics Inc’s year-ago sales were $nanFor the next quarter, 2.0 analysts are estimating revenue of $nan. There is a high estimate of $nan for the next quarter, whereas the lowest estimate is $nan.
A total of 2 analysts have provided revenue estimates for GANX’s current fiscal year. The highest revenue estimate was $nan, while the lowest revenue estimate was $nan, resulting in an average revenue estimate of $nan. In the same quarter a year ago, actual revenue was $55kBased on 2.0 analysts’ estimates, the company’s revenue will be $nan in the next fiscal year. The high estimate is $nan and the low estimate is $nan.
